SUMMARY Spondyloarthritis (SpAs) are a group of chronic inflammatory diseases that affect joints and enthesis with a possible involvement of other districts such as skin, eye and bowel. In SpAs, the inflammatory process could lead to both erosive damage (as in peripheral joint involvement of psoriatic arthritis), or bone formation (as in ankylosing spondylitis) with a reduction in function and quality of life. Recently, Mesenchimal stem cells (MSCs) transplant was used in different diseases, including autoimmune and inflammatory diseases, with the aim of repairing tissue damage, exploiting their regenerative capacity. However, MSCs also proved to have an immune-modulatory capacity due to their interaction with the cells of the immune system. The aim of this brief paper was to review the possible pathogenic role and the new perspective of MSCs use in SpAs.
n INTRODUCTION S pondyloarthritis (SpAs) are a group of inflammatory diseases characterized by chronic inflammatory spondylitis, chronic synovitis and enthesitis associated with extra-articular manifestations (i.e., psoriasis, uveitis and inflammatory bowel disease). Traditionally, the term SpA comprises a group of interrelated yet distinguishable disorders (1, 2) . These disorders are ankylosing spondylitis (AS), psoriatic arthritis (PsA), arthritis/SpA associated with ulcerative colitis or with Crohn's disease, reactive arthritis and undifferentiated SpA. All SpAs subgroups have in common a familial aggregation, and are associated to varying extents with human leukocyte antigen-B27 (HLA-B27), providing evidence for a shared genetic background (2, 3) . One of the most important aspects of SpAs was the involvement of bone and cartilage tissue: the development of inflammation at entheseal and synovial sites can lead to tissue damage that could be predominantly erosive, such as in PsA, or could be expressed as new bone formation such as in AS. Several studies reported an occurrence of bone erosions ranging from 46 to 62% of patients affected by PsA, leading to joint destruction and severe reduction of function and quality of life (4) . Likewise, the new bone formation with the fusion of the spine in the late stage could lead to a severe reduction of function and quality of life in AS (5) . The introduction of biologic drugs, such as the tumor necrosis factor (TNF) blockers, the anti-interleukin (IL) 12/23 and anti-IL17 blockers for the treatment of SpAs, has been considered the greatest breakthrough over the past 50 years (6-10). However, their efficacy in slowing radiographic progression of the disease, in healing erosions or reversing bone formation is far from being proven. Since damaged and/or deformed joints cannot be repaired, a novel treatment strategy aimed at both anti-inflammation and bone regeneration/ healing is needed, especially in the long lasting form. In this context, the recent use in different clinical settings of mesenchimal stem cells (MSCs) could provide a possible new approach to treatment. In fact, it has been shown that MSCs are im- 
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tive tissues. The International Society for Cellular Therapy established the minimum criteria that must be met in order to classify a stem cell as MSCs: it must be: 1. adherent to plastic under standard culture conditions; 2. express CD105, CD73 and CD90; 3. lack expression of CD45, CD34, CD14 or CD11b, CD79a or CD19 and human leukocyte antigen (HLA)-DR; 4. differentiate from osteoblasts, adipocytes and chondroblasts in vitro (12) . MSCs tissue source is another area of active investigation: bone marrow, adipose tissue and umbilical cord blood have been most commonly used, but the wide distribution of these cells has generated interest in other locations such as synovium and periosteum (13, 14) . Bone marrow-derived MSCs (BM-MSCs) are part of the haematopoietic niche, where they support haematopoiesis such as MSCs coming from other tissues supporting connective tissue homeostasis. The physiological role of MSCs is to ensure that when cells within tissues expire naturally, these can be easily replaced to provide physiological balance in the organism but also to serve as a reserve for damaged or compromised adult tissues requiring more extensive repair, regeneration or expansion. Curiously, the synovial membrane has proved to be a great source for the functionality of MSCs with highest multi-potentiality for adipogenesis, osteogenesis, chondrogenesis and myogenesis (15) (16) (17) . 
Immunoregulation
Different studies demonstrated that MSCs orchestrate important immunologic functions through modulation of the local inflammatory response (18) , mainly in autoimmune diseases. It has been demonstrated that inflammation could alter the expression and function of MSCs; in fact, some studies showed that prevalence of MSCs was significantly lower in the synovial fluid of rheumatoid arthrtitis (RA) patients than in that of osteoarthritis patients (19, 20) . In addition, there was a negative reportant in the pathogenesis of many autoimmune diseases due to their proliferating and differentiating potential and because of their potent immune-modulatory and antiinflammatory properties (11) . The aim of this paper was to review briefly the role of MSCs in the pathogenesis and treatment of SpA and to discuss the current border of cellular treatment in these diseases. (29), by decreasing the expression of human leukocyte antigen DR, CD80 and CD86 co-stimulatory molecules on antigen presenting cells (29) , and through the inhibitory effects on proliferation of both resting and IL-2 activated natural killer (NK) cells. Moreover, a direct inhibition on the cytotoxic capabilities of NK cells (30) has been demonstrated. The immune-regulatory properties of cultured synovial MSCs are less well known but the data available seems to show that they have similar functions in respect to BM-MSCs (31, 32 In SpAs, inflammation can be found both in synovium and enthesis: in these anatomical sites, MSCs are present and it has been hypothesized that resident MSCs may function as a reservoir of stem cells for the regeneration or repair of joint tissues such as the articular cartilage, which have limited repair potential (36) . Experimental data confirm the higher speed and quality of lesion repair of mesenchymatous cell injection with respect to chondrocyte injection in a rat model of degenerative joint disease (37) . Other studies evaluated the optimal conditions for the differentiation of MSCs to tenocytes, chondrocytes, or bone cells The results showed that mesenchymatous cell differentiation toward a tendon or bone phenotype depended on the degree of tensile loading: higher tensile loads promoted osteogenic differentiation (38) . Mechanosensitive calcium permeable channels, such as the TRP channel, generate changes in intracellular calcium concentration in response to various mechanical stimuli (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) . Activation of these channels at the level of plasma membrane of MSCs would induce intracellular calcium release and confirm the hypothesis that the mechanical tension could also activate MSCs in the pathological process that leads to the development of the SpAs (55-57). The activation and differentiation of MSCs at entheseal sites is also strongly influenced by paracrine signals (including the collagen-1 or fibronectin concentration), at least in the absence of strong tensile loads. High fibronectin concentrations promote osteogenic differentiation, whereas high collagen-1 concentrations inhibit osteogenic differentiation and promote differentiation to tenocytes (38) . These findings could provide indirect evidence of the involvement of MSCs in the pathological process affecting the enthesis in SpAs. However, the precise mechanism linking the inflammatory process to osteoproliferation in SpA is still unknown. Other data derive from studies on osteoarthritis: human osteophytes have shown them to contain cells exhibiting a mesenchymatous cell phenotype and probably originating in the periosteum (58, 59 The regenerative, immunosuppressive and anti-inflammatory properties of cultured MSCs led to the development of trials for their therapeutic potential in preclinical models of inflammatory arthritis. As discussed above, several studies suggested that bone marrow-or adipose-derived MSCs have the ability to reset the immune system by reducing the pro-inflammatory Th1/Th17 response and enhancing the protective regulatory T cell response (61) . Bone marrow has been the historic source site of MSCs and is the best studied. Some authors have found a trophic advantage with BM-MSCs; however, newer evidence suggests that BM-derived MSCs may be less potent in comparison to MSCs that reside in adipose tissue and this could be due to the physiologic stress and high turnover present in bone marrow compared with adipose (62, 63) . The primary intent of the use of MSCs was to exploit their regenerative capacity to repair cartilage or bone damage in both inflammatory or degenerating pathologies such as RA or osteoarthritis (64) . In this context, several studies on animal models of osteoarthritis have been performed with alternating results because of the number of variables. Moreover, there are other aspects still to be considered before translating this approach into clinical practice. The first issue to consider is donor source. Autologous products may be safer and almost free from immunogenicity, but in different studies, allogenic MSCs were used. Although MSCs are immuno-privileged with low levels of MHC-molecules, allogenic MSC have been shown to be immunogenic and are immune rejected by MHC class I-and class II-mismatched recipient mice (65) . 
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are more common, probably due to fewer regulatory issues, even when injected directly into a joint. The second issue to consider is the possibility that injected MSCs could spread to other tissues. However, recent research demonstrates that MSCs injected in a joint remain localized to the transplant site without mobilization to distant organs (66) . Another important issue to consider when administrating MSCs was the safety of transplantation and/or infusion/injection. Evidence is scarce; however, MSCs treatment could be considered safe. One study suggested that neither tumors nor infections were observed in a mean of 75 months after autologous BM-MSCs transplantation among 45 large joints in 41 patients (67) . To exploit their immune-modulatory properties, MSCs can be directly infused in the blood stream, alongside their action as local regenerative factors. Two large studies on RA patients have been published: in the first, 136 patients with active RA who had inadequate responses to traditional medication received 40x10 6 allogeneic umbilical-cordderived MSC (UC-MSC) and 36 patients only received the cell-solvent without the cells (68) . Patients were divided into two groups for different treatment: one group was given disease-modifying anti-rheumatic drugs (DMARDs) without UC-MSC, the other was given DMARDs plus UC-MSC via intravenous injection. The serum levels of TNF and IL-6 decreased after the first UC-MSC treatment, while the percentage of regulatory T cells of peripheral blood was increased. The treatment induced a significant improvement of disease activity and quality of life. The therapeutic effects were maintained for 3 and 6 months without continuous administration, correlating with the increased percentage of regulatory T cells of peripheral blood. In comparison, there were no such benefits observed in the control group of DMARDs without UC-MSC. No patients showed acute serious side-effects either during or after UC-MSC infusion, and 4% showed mild adverse effects during the infusion, such as chill and/or fever, which disappeared within 2 h without any treatment and the authors reported that no major abnormal findings in hematologic or serum chemical profiles were found in the study. Thus, these data indicate that treatment with DMARDs plus UC-MSC may provide safe, significant, and persistent clinical benefits for patients with active RA (68) . The second study presented at the American College of Rheumatology in San Diego in 2013 showed that in 53 refractory RA patients, allogeneic adipose-derived MSC infusion was safe at high dose (69) . Dose-limiting safety signals were not identified and only one of the 53 patients experienced a serious adverse event leading to discontinuation of the treatment (lacunar infarction). Other adverse events were mild and transient (69) . In this context, Wang et al. recently published the first clinical trial on the efficacy and safety of human MSCs in the treatment of AS. The aim of the study was to assess the antiinflammatory properties of MSCs rather than their ability to repair tissue damage. In this study, patients with active disease received four intravenous infusions of allogenic MSCs on days 0, 7, 14, and 21. The results showed that the percentage of ASAS20 responders at the fourth week was 77.4% (24/31). Furthermore, in this study the authors evaluated the effects of MSCs infusion on the inflammatory lesions at MRI. The average total inflammation extent detected by MRI decreased from baseline to 4 th week (p>0.05) and to 20 th week (p<0.05). Infusion of MSCs was well tolerated and no adverse events were reported. The authors stated that intravenous infusion of MSCs is a feasible, safe, and promising treatment for patients with AS. However, this study had some limitations such as the lack of a control group, the small number of enrolled patients and the lack of assessment of radiographic progression (70) . 
were published on the usage of hematopoietic stem cells transplantation in cases of SpA associated with leukemia, with encouraging results. However, there were complications of hematopoietic stem cells transplantation in the treatment of autoimmune diseases, which included availability, treatment-related mortality, infective and endocrinological complications, treatmentassociated toxicity, and secondary autoimmune diseases and malignancies (71, 72) . MSCs, on the contrary, could represent a future treatment, with a possible safe and tolerable profile, for inflammatory arthritis such as SpAs. However, several questions remains about their use in humans: syngeneic or allogeneic cells, the tissue of origin of MSCs, timing of treatment, the number of cells injected, the route of injection, treatment regimes and different culture conditions. Potential long-term side effects as well as ethical considerations should be taken into account and further studies are needed. 
